Differentiate your biosimilars
Premium biosimilars, like conventional biosimilars, are generic versions of recombinant protein therapeutics which have to demonstrate bioequivalence for regulators.
Premium biosimilars are tailor-made for the commercial requirements of their specific markets and the preferences of the end-user. This makes them ‘first among equals’, with differentiators from ordinary biosimilars that enable them to capture market share while remaining bioequivalent.
These differentiators provide competitive advantages for premium biosimilars that include quality consistency, process efficiency, process simplicity, and competitive pricing. Delivering the correct blend of characteristics to create a market dominating premium biosimilar can require multi-parameter bespoke optimisation which is not feasible for standard methods.
Phenotypeca’s QTL technology selects parent strains from the world’s largest and most diverse library. Each round of breeding generates billions of progeny for screening. Quantitative trait loci technology utilises the entire genome to identify the locations and variations that are critical for the desired protein characteristics. These unique and proprietary combinations of capabilities harness the full power of biology to deliver multi-parameter targeted optimisation.
Because Phenotypeca’s patent estate prevents competitors from developing rival biosimilars with similar advantages, premium biosimilars have the added potential to entrench their market dominance and drive revenue growth over the longer term.
Validated
Phenotypeca receives support from the Bill & Melinda Gates Foundation to develop QTL technology that has been used to generate recombinant albumin which is a key excipient of certain vaccines, making them more accessible and affordable to low and middle income countries. The technology is currently harvesting the formulary for Phenotypeca’s continuously expanding portfolio of premium biosimilars.
Collaborate with us
We’re actively seeking capable and ambitious partners to exploit the commercial opportunities that our QTL technology affords. If you’re looking to develop a biosimilar with market leading potential, interested in expanding and/or accelerating the growth of your existing biosimilar portfolio, or seeking to exploit the growth potential of premium biosimilars, please contact us.
